secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001880
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma appoints Christopher Cooper interim CEO; founder Dritschilio CSO & Chairman
--------------------------------------------------------------------------------

- Christopher Cooper appointed interim CEO effective March 30, 2025.
- Founder Dr. Anatoly Dritschilio becomes Chief Scientific Officer, remains Chairman of the Board.
- Amended employment agreement: 3-year term, $274,000/year base salary, 12-month severance.
- Dritschilio tasked with completing Phase 2 Ropidoxuridine glioblastoma trial by 2026, initiating Phase 3 by 2028.
- Restructuring aims to add expertise in business and capital markets activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/0001641172-25-001880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer